Drug Profile
Research programme: lysosphingolipid receptor agonists - Actelion
Alternative Names: Actelion-2; SIP1 agonists - Actelion/RocheLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Class
- Mechanism of Action Immunomodulators; Lysosphingolipid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders